open access

Vol 23, No 2 (2018)
Original research articles
Published online: 2018-03-01
Submitted: 2017-04-23
Get Citation

Thymic tumors and results of radiotherapy

Sureyya Sarıhan, Ahmet Sami Bayram, Cengiz Gebitekin, Omer Yerci, Deniz Sıgırlı
DOI: 10.1016/j.rpor.2017.12.002
·
Rep Pract Oncol Radiother 2018;23(2):97-104.

open access

Vol 23, No 2 (2018)
Original research articles
Published online: 2018-03-01
Submitted: 2017-04-23

Abstract

Aim

The aim of this study was to evaluate thymic epithelial tumors (TETs) for treatment outcomes and prognostic factors on survival.

Background

TETs are very rare neoplasms and multidisciplinary approach is recommended according to prognostic factors.

Materials and methods

Between 1995 and 2013, 31 patients were treated with median 5400[[ce:hsp sp="0.25"/]]cGy (range: 1620–6596[[ce:hsp sp="0.25"/]]cGy) radiotherapy (RT). Eleven patients received adjuvant or concurrent chemotherapy. There were 25 thymomas, 4 thymic carcinomas and 2 thymic neuroendocrin carcinomas. According to Masaoka, staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) prognostic risk groups. Survival was calculated from diagnosis.

Results

In January 2016, 22 cases were alive with median 51.5 months (range: 2–170.5) follow-up. Recurrences were observed in 29% of patients in median 29.5 months (range: 6.5–105). Local control, mean overall (OS) and disease-free survival (DFS) rates were 86%, 119 and 116 months, respectively. There was a significant difference for R0 vs. R+ resection (81% vs. 43%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.06, and 69% vs. 46%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.05), Masaoka stage I–II vs. III–IV (75% vs. 52%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.001, and 75% vs. 37%, p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.001), and also prognostic risk groups (100% vs. 89% vs. 48%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.003, and 100% vs. 87% vs. 27%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.004) in terms of 5-year OS and DFS, respectively.

Conclusion

In our study, prognostic risk stratification was shown to be a significant predictor of survival. There is a need to investigate subgroups that may or may not benefit from adjuvant RT.

Abstract

Aim

The aim of this study was to evaluate thymic epithelial tumors (TETs) for treatment outcomes and prognostic factors on survival.

Background

TETs are very rare neoplasms and multidisciplinary approach is recommended according to prognostic factors.

Materials and methods

Between 1995 and 2013, 31 patients were treated with median 5400[[ce:hsp sp="0.25"/]]cGy (range: 1620–6596[[ce:hsp sp="0.25"/]]cGy) radiotherapy (RT). Eleven patients received adjuvant or concurrent chemotherapy. There were 25 thymomas, 4 thymic carcinomas and 2 thymic neuroendocrin carcinomas. According to Masaoka, staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) prognostic risk groups. Survival was calculated from diagnosis.

Results

In January 2016, 22 cases were alive with median 51.5 months (range: 2–170.5) follow-up. Recurrences were observed in 29% of patients in median 29.5 months (range: 6.5–105). Local control, mean overall (OS) and disease-free survival (DFS) rates were 86%, 119 and 116 months, respectively. There was a significant difference for R0 vs. R+ resection (81% vs. 43%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.06, and 69% vs. 46%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.05), Masaoka stage I–II vs. III–IV (75% vs. 52%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.001, and 75% vs. 37%, p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.001), and also prognostic risk groups (100% vs. 89% vs. 48%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.003, and 100% vs. 87% vs. 27%, p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.004) in terms of 5-year OS and DFS, respectively.

Conclusion

In our study, prognostic risk stratification was shown to be a significant predictor of survival. There is a need to investigate subgroups that may or may not benefit from adjuvant RT.

Get Citation

Keywords

TET; TC; NEC; OS; DFS; R0; R+; R1; R2; RT; CHE; WHO; PF; CT; PET/CT; 3D-CRT/IMRT; MG; cm; LC; 4D-CT

About this article
Title

Thymic tumors and results of radiotherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 2 (2018)

Pages

97-104

Published online

2018-03-01

DOI

10.1016/j.rpor.2017.12.002

Bibliographic record

Rep Pract Oncol Radiother 2018;23(2):97-104.

Keywords

TET
TC
NEC
OS
DFS
R0
R+
R1
R2
RT
CHE
WHO
PF
CT
PET/CT
3D-CRT/IMRT
MG
cm
LC
4D-CT

Authors

Sureyya Sarıhan
Ahmet Sami Bayram
Cengiz Gebitekin
Omer Yerci
Deniz Sıgırlı

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl